Cover Image
市場調查報告書

全球顯影劑市場

Imaging Agents

出版商 Global Industry Analysts, Inc. 商品編碼 236838
出版日期 內容資訊 英文 384 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球顯影劑市場 Imaging Agents
出版日期: 2016年09月01日 內容資訊: 英文 384 Pages
簡介

本報告提供全球顯影劑市場相關調查,為您彙整美國,加拿大,日本,歐洲,亞太地區,中東,南美等地區別分析,今後的市場預測,及打入市場的主要企業簡介等資料。

第1章 簡介,調查方法,產品定義

第2章 摘要整理

  • 產業概要
    • 顯影劑:概要
    • 市場方案:不景氣和未來趨勢
    • 現在及未來分析
    • 各地區分析
    • 各市場區隔分析
    • 促進成長要素
    • 阻礙成長要素
    • 核醫學
    • 用於核醫學的PET及SPECT放射性同位素
    • 心臟及癌症的放射性醫藥品
    • 癌症的發病率上升
    • 醫療費擴大促進成長
    • 高齡化 其他
  • 市場區隔檢討
    • 顯影劑
    • 顯影劑的熱門品牌
    • X光掃瞄
    • MRI
    • 超音波
    • 診斷用放射性醫藥品
    • 免疫偶聯物
  • 市場趨勢與課題
  • 競爭
    • 市場結構
    • 市場進入者
    • 核磁共振攝影市場主要企業
    • 超音波顯影劑市場
    • 診斷用放射性醫藥品
  • 全球醫療用影像市場:概要
    • 醫療用影像:臨床診斷的環境變化
    • 各種影像系統別模式比較
    • 不景氣影響下的醫療用影像產業 其他
  • 產品概要
  • 技術趨勢
  • 產品上市/認證/臨床實驗
  • 近幾年的產業活動
  • 主要企業
  • 全球市場預測

第3章 市場

  • 美國
  • 加拿大
  • 日本
  • 歐洲
    • 法國
    • 德國
    • 義大利
    • 英國
    • 西班牙
    • 俄羅斯
  • 亞太地區
    • 中國
    • 印度
  • 中東
  • 南美
  • 其他

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MCP-3336

This report analyzes the worldwide markets for Imaging Agents in US$ by the following Product Segments: Contrast Media (X-Ray/CT, MRI, & Ultrasound), and Diagnostic Radiopharmaceuticals. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East & Africa, and Latin America. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 53 companies including many key and niche players such as -

Aytu BioScience, Inc.
Bayer Healthcare Pharmaceuticals
Bracco Diagnostics, Inc.
Daiichi Sankyo Company Limited
Eisai Co., Ltd.

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

  • Study Reliability and Reporting Limitations
  • Disclaimers
  • Data Interpretation & Reporting Level
    • Quantitative Techniques & Analytics
  • Product Definitions and Scope of Study
    • A. Contrast Media
        • X-Ray/CT Contrast Media
        • Magnetic Resonance Imaging (MRI) Contrast Media
        • Ultrasound Contrast Media
    • B. Diagnostic Radiopharmaceuticals

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW

  • Imaging Agents: A Quick Primer
  • Market Outlook
  • Current and Future Analysis
  • Analysis by Region
    • United States: Holds the Largest Share
    • Developing Countries: Potentially Lucrative Market
  • Analysis by Segment
    • Contrast Media: Giving Way to Contemporary Offshoots
    • Diagnostic Radiopharmaceuticals to Outdo Contrast Media
      • Nuclear Medicine: A Potential Growth Avenue for Dx Radiopharmaceuticals
      • Select PET and SPECT Radioisotopes Used in Nuclear Medicine
      • Select Cardiology and Oncology Radiopharmaceuticals
  • Major Growth Drivers in a Gist
  • Select Market Growth Restraints

2. SEGMENTAL OVERVIEW AND COMPETITIVE LANDSCAPE

  • Market Structure
  • Key Market Participants
  • Contrast Media
  • Popular Brands of Contrast Agents
  • X-ray Contrast Media
    • Table 1: Annual Sales of Select Key Iodinated Contrast Agents: 2014 & 2015 (In US$ Million) (includes corresponding Graph/Chart)
  • MRI Contrast Media
    • Market Scenario
    • Key Players in the MRI Market
      • List of FDA Approved Gadolinium-Based Contrast Agents (GBCA) for CNS MRI
      • List of EMA Approved Gd Chelated Contrast Agents
    • Controversies over GBCAs Refuse to Die Down
      • A Comparison of Approved Gadolinium-based Contrast Agents
      • Select GBCA-Induced Toxicities
      • Regulators Spring into Action
      • European Medicines Agency's NSF Risk-based Classification of GBCAs
      • Competitive Re-arrangement Surfaces as Safety Concerns on GBCAs Reach their Peak
    • Table 2: Annual Sales of Select Key Gadolinium-Based Contrast Agents: 2014 & 2015 (In US$ Million) (includes corresponding Graph/Chart)
    • Glucose - Can it Replace GBCAs?
  • Ultrasound Contrast Media
    • Limited System Use Curtails Demand for Ultrasound Contrast Agents; Potential for Further Growth Exists
    • CEUS and Ultrasound Contrast Agents - A Dichotomy in Approach in Europe and the US
      • A Comparison of Major Approved UCAs
      • Approved Ultrasound Contrast Agents by Country and Application
  • Contrast Media API Production - Still Largely In-house
    • A Peek into API Supplier Space for Select Contrast Media
  • Diagnostic Radiopharmaceuticals
  • Market Overview
  • Commonly Used Diagnostic Radiopharmaceutical Agents
    • Major Isotopes and their Diagnostic Applications
    • Select FDA Approved Diagnostic Radiopharmaceuticals by Indication
  • New Imaging Agent for Radiopharmaceutical Scans
  • Prospects for Radiopharmaceutical Agents in PET and SPECT Appear Brighter

3. MARKET TRENDS & ISSUES

  • Expansion of Molecular Imaging Platform is Key to Future Growth
  • Growing Interest in Image Guided Surgery Offers New Opportunities
  • Fluorescence Optical Imaging - Opens New Avenues
  • Coronary CT Angiography Opens Up Opportunities for Contrast Agents
  • List of Iodine-Containing Contrast Agents for Coronary CT Angiography
  • Targeted Imaging - A Game Changer in the Making?
  • Clinical Acceptance of MRI Systems on Rise
  • Nanomaterials Taking the Center Stage
  • New Nanoparticle Contrast Agents on the Horizon Show Promise
  • Gadolinium Coated Nanoparticles - A Promising Imaging Agent
  • Growing Focus on Development of Gold Nanoparticles in X-Ray Imaging
  • Imaging Agents Make a Welcome Impact in the Field of Alzheimer's Disease
  • List of FDA Approved Alzheimer's Diagnostic Imaging Agents
  • Contrast-Enhanced Tomosynthesis Expands Opportunities
  • Hyperpolarized Gases as Contrast Agents
  • Multi-Modal Imaging: Combating Contrast Medium Inconsistencies
  • Falling Prices Turn on the Heat
  • Ultrasound Contrast Agents in Diagnosis of Kidney Ailments
  • FDA Mandates Black Box Warning Label for Gadolinium-Based MRI Contrast Agents
  • PET: A Prime Growth Driver for Diagnostic Radiopharmaceuticals
  • Innovative Radiotracers to Boost Cardiac Applications for SPECT and PET Modalities
  • Global CVD Stats
    • Table 3: Global Annual Medical Cost of CVD in US$ Billion (2010-2030) (includes corresponding Graph/Chart)
    • Table 4: Fatalities by Heart Conditions - Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others (includes corresponding Graph/Chart)
  • Opportunities on Rise for Fluorine-Based Myocardial Perfusion Agents
  • Unfounded Fears of Radiation Exposure: A Major Concern for Nuclear Diagnostics
  • Rising Incidence of Cancer - A Major Growth Driver
    • World Cancer Statistics - Incidence and Mortality Data
    • Table 5: World Cancer Incidence by Geographic Region (2012): Number of New Cancer Cases Reported in Thousands for Asia-Oceania, Europe, North America, Latin America & the Caribbean, and Africa (includes corresponding Graph/Chart)
    • Table 6: World Cancer Mortality by Geographic Region and Gender (2012): Number of Cancer-Related Deaths in Thousands for Asia-Oceania, Europe, North America, Latin America & the Caribbean, and Africa (includes corresponding Graph/Chart)
  • Improving Healthcare Expenditure to Foster Growth
    • Table 7: Healthcare Spending as % of GDP by Region (2016E) (includes corresponding Graph/Chart)
    • Table 8: Healthcare Spending as a Percentage of GDP in Select Countries (2013) (includes corresponding Graph/Chart)
    • Table 9: Per-Capita Healthcare Spending in Select Countries (2013) (includes corresponding Graph/Chart)
  • Ageing Population - A Vital Demography
    • Table 10: Percentage Growth of 65+ Population in North America, Europe, Asia, and Latin America (includes corresponding Graph/Chart)
    • Table 11: Global Population Statistics for the 65+ Age Group (2015) (includes corresponding Graph/Chart)
    • Table 12: Comparison of Aging Population by Country (1980, 2015 & 2050): Percentage Share of Population Aged Above-65 Years of the Overall Population for Select Countries (includes corresponding Graph/Chart)
    • Table 13: Life Expectancy for Select Countries in Number of Years: 2015E (includes corresponding Graph/Chart)
  • A Peek into Pricing Dynamics
  • A Synoptic Overview
  • Pros & Cons
  • Positive Factors Driving Prices
  • Negative Factors Bearing Down on Prices
  • Reimbursements
  • Europe
  • United States

4. GLOBAL MEDICAL IMAGING MARKET - AN OVERVIEW

  • Medical Imaging - Changing the Landscape of Clinical Diagnosis
    • Table 14: Global Imaging Equipment Market by Modality (2015): Percentage Breakdown of Value for CT, MRI, Nuclear, Ultrasound and X-Ray (includes corresponding Graph/Chart)
    • Table 15: Global Imaging Equipment Market by Geographic Region (2015): Percentage Breakdown of Value for China, Europe, Japan, North America and Rest of World (includes corresponding Graph/Chart)
    • Table 16: Global Medical Imaging Equipment Installed Base (2013): Percentage Share Breakdown of Volume Installations for X-ray, Ultrasound, Magnetic Resonance, Computed Tomography, and Nuclear Medicine/PET by Country/Region (includes corresponding Graph/Chart)
  • Comparison of Modalities by Various Imaging Systems
  • Archaic X-Ray Imaging Modalities Paving Way for Digital X-Rays
  • Ultrasound Holds its Fort in the Medical Imaging Market
    • Table 17: World Ultrasound Market by Application (2015): Percentage Breakdown of Usage for Cardiology, Radiology and Others (includes corresponding Graph/Chart)
  • Technological Advancements Favor MRI Market
    • Table 18: Global MRI Usage by Application Area (2013) (includes corresponding Graph/Chart)
  • Comparison of MRI against Other Imaging Modalities
  • Nuclear Medicine Imaging Equipment Presents Lucrative Growth Opportunities
    • Table 19: Worldwide Installed Base of Nuclear Imaging Devices by Modality (2013) Percentage Share Breakdown of Number of Installations for SPECT and PET (includes corresponding Graph/Chart)
  • Hybrid Imaging to Herald a New Era of Diagnosis
  • Hybrid PET/MRI Systems: A New Fusion
    • Price Sensitivity & Competition from Alternatives Limit Market Potential
    • Unfounded Fears of Radiation Exposure Hinder Growth
    • Bottlenecks in Developing Markets
  • Use of Contrast Agents in Other Imaging Modalities
  • Fluoroscopy
  • Computed Tomography

5. PRODUCT OVERVIEW

  • Contrast Agents
  • Contrast Media: How Do They Function?
    • Where Are They Used...?
  • Evolution of Contrast Media: A Profile
    • Bismuth Nitrate: Beginning of Contrast Agents
  • Imaging Agents: Significant Developments in the Last Fifty Years
  • Schering Develops First Intravenous Contrast Agent
  • MRI: Creating a New Era for Contrast Agents
  • A Peek into the Finer Points of Differences Among Contrast Media
  • Second Generation Non-Ionic Contrast Agents: An Introduction
  • Choice of the Contrast Medium: A Weighty Decision
  • Factors Affecting choice of Imaging Agents
  • Taxonomy
  • Types of Contrast Media
    • X-Ray Contrast Medium
      • First Generation High Osmolar Contrast Media
      • Second Generation Low Osmolar Contrast Media or LOCM
    • Table 20: Comparative Analysis of Structure of Non-ionic and ionic X-ray Contrast Media
    • MRI Contrast Medium
      • Role of Contrast Enhancement in MR Angiography (MRA)
      • MRI Contrast Agents for the Liver
      • Paramagnetic Extracellular Contrast Agents
      • Hepatobiliary Gadolinium Chelates
      • Superparamagnetic Iron Oxide Particles
    • Ultrasound Contrast Medium
      • Ultrasonographic Contrast Media: What Are They?
      • Ultrasound Contrast Enhancement in Cardiology
      • Functionalities of Vascular Ultrasound Contrast Agents
  • Diagnostic Radiopharmaceuticals
    • A Delineate of Diagnostic Radiopharmaceuticals
    • Diagnostic Radiopharmaceuticals: A Technical Run-Through
    • Applications
    • Classification
      • Cardiology Diagnostics
      • Non-cardiology Diagnostics
      • Molecular Imaging Modalities in Radiopharmaceutical Diagnostics
      • Planar Imaging
      • Positron Emission Tomography (PET)
      • Applications of PET
      • Commonly used Radioisotopes in PET Scans
      • Major PET Isotopes and their Applications
      • Single Photon Emission Computed Tomography (SPECT)
      • Applications of SPECT
      • Commonly used Radioisotopes in SPECT Scans

6. TECHNOLOGY DYNAMICS

  • Proprietary Technologies Making In-Roads
  • Advanced Magnetics' Proprietary Colloidal Superparamagnetic Particle Technology
  • Enzon's Single Chain Antigen-Binding Technology
  • Immunomedics' Antibody Technology
    • First Generation
    • Second Generation
    • Third Generation
  • NeoRx's "Painting the Target" Technology
    • Stage - I
    • Stage - II
    • Stage - III
  • Gas Encapsulation Technology for Ultrasound Contrast Media
  • Pharmacyclics' Texaphyrin Technology
  • Regulatory Bodies
  • Entry Barriers
  • Research Driven Markets
  • Highly Competitive Market
  • Economies of Scale
  • Substitutes in Agents Manufacturing
  • New X-ray Diagnostic Agents
  • Amide-based Macrocyclic Ligands - Potential MRI Agents
  • Gadolinium (III) Complexes - Potential MRI Contrast Agents
  • Metal-Containing Compounds Act As Potential Contrast Agents
    • Therapeutic Applications
    • Diagnostic Applications
  • Magnetic Gels as Potential MRI Contrast Agents
  • PFCs as Diagnostic Contrast Agents
  • Saline Flushes To Help Ensure Accurate Delivery of Contrast Agents

7. PRODUCT LAUNCHES/APPROVALS/ CLINICAL TRIALS

  • Lantheus Begins Shipment of Xenon Xe 133 Gas
  • Otsuka Launches ORALTAG(tm) in the US
  • Advanced Accelerator Applications Receives FDA Approval for Netspot
  • Blue Earth Diagnostics Secures FDA Approval for Axumin(tm)
  • Bayer Obtains FDA Approval for Gadavist(r) for MRA for Supra-aortic Arteries
  • Bracco Secures FDA Clearance for LUMASON in Ultrasonography of the Liver for Lesion Characterization
  • Bracco Obtains FDA Clearance for READI-CAT(r) 2 and READI-CAT(r) 2 SMOOTHIE NDA
  • Bracco Bags FDA Approval for E-Z-HD for GI Tract Radiohraphic Exams
  • Bracco Imaging Rolls Out EmpowerCTA(r)+ Contrast Injection System
  • Bayer Obtains Label Extension for Gadovist(r) in the EU
  • Bayer Receives Approval for Gadovist(r) for Use with MRI in Japan
  • Bayer Secures FDA Approval for Gadavist(r) for Use in Infants
  • Bracco Makes ISOVUE(r) Available for POC Use in CT Suite
  • Bracco Bags FDA Clearance for Lumason(tm) for Suboptimal Echocardiograms in Adults
  • GE Introduces Vizamyl Alzheimer's Imaging Agent
  • Navidea Biopharmaceuticals Obtains FDA Approval for Lymphoseek Injection for New Indication
  • Bayer Obtain FDA Approval for Gadavist for Breast Cancer Evaluation
  • GE Healthcare Gets Norwegian Medicines Agency Approval for Sonazoid(tm) to Detect Focal Liver Lesions
  • ImaginAb Announces Initial Phase I/IIa Results for 89Zr-Df-IAB2M Prostate Imaging Agent
  • Piramal Imaging Receives FDA Approval for Neuraceq PET Imaging Agent
  • NanoHybrids Introduces Premium Product Line of Imaging Contrast Agents
  • CMC Contrast AB Obtains Orphan Drug Designation from the US FDA for CMC-001
  • GE Healthcare Obtains FDA Approval for its Oslo Plant to Manufacture Optison Heart Imaging Agent
  • GE Healthcare Gets FDA Approval for Vizamyl Alzheimer's Imaging Agent
  • GeccoDots Launches New Contrast Agent
  • Navidea Biopharmaceuticals Signs Agreement with Nordion
  • Navidea Biopharmaceuticals Launches Lymphoseek(r)
  • GE Healthcare Gets Expanded FDA Approval for AdreView
  • Guerbet Obtains FDA Approval for Dotarem MRI Contrast Agent
  • PerkinElmer Introduces GFR-Vivo 680
  • Navidea Obtains FDA Approval for Lymphoseek(r) Injection
  • Navidea Signs Agreement with Maimonides Medical Center to Collaborate on Clinical Trial Utilizing Lymphoseek(r) Injection in Colorectal Cancer

8. RECENT INDUSTRY ACTIVITY

  • Cell>Point Inks Licensing Agreement with UEP for Oncardia
  • FluoroPharma Inks Agreement to Take Over Ground Fluor Pharmaceuticals
  • Bracco Diagnostics's LUMASON(r) Obtains Innovative Technology Designation from Vizient
  • Blue Earth Diagnostics Establishes Operations in the US
  • Ipsen and 3B Pharmaceuticals Ink Licensing Deal for Oncology Radiopharmaceuticals
  • Lantheus Divests Gludef(r) Business in Canada to Isologic
  • Guerbet Acquires Mallinckrodt's Contrast Media and Delivery Systems Business
  • Bracco Obtains CMS Pass-Through Status for its Lumason(r) Ultrasound Contrast Agent
  • Guerbet Inks Deal with Beijing Kyuan Pharmaceutical for Lipiodol(r) Ultra-Fluid
  • Bracco Expands Group Purchasing Agreement with Amerinet to Include Lumason
  • Guerbet Inks Agreement with Fuji Pharma to Distribute Contrast Media in Japan
  • Bayer Inks Agreement with Polysan to Produce Contrast Media in Russia
  • Blue Earth Diagnostics' Fluciclovine (18F) Obtains Orphan Drug Designation for Glioma Diagnosis in US and Europe
  • Aytu BioScience Acquires ProstaScint from Jazz Pharmaceuticals
  • PETNET Solutions Inks Agreement with Blue Earth Diagnostics for Fluciclovine Manufacture and Distribution
  • Ipsen to Acquire OctreoPharm Sciences
  • IBA Molecular to Divest US Operations to Illinois Health and Science
  • Lantheus Obtains sNDA from FDA for Manufacturing NEUROLITE(r) at Jubilant HollisterStier
  • Lantheus Inks Supply Agreement for Xenon 133 with IRE
  • AAA to Acquire GE's Italian FDG-PET Imaging Agent Business
  • ImaginAb Establishes Subsidiary in Japan
  • ImaginAb and Duke-NUS Partner to Develop in vivo Molecular Imaging Agents
  • AC Immune and Piramal Imaging Strike Deal to Develop Alzheimer's Imaging Agent
  • Blue Earth Diagnostics Commences Operations
  • Enlyton Bags SBIR Contract from NCI for Pre-Clinical Development of Tumor Imaging Agent
  • Guerbet Obtains FDA Approval for Lipiodol Contrast Agent Manufacturing Plant
  • Integrated Diagnostics Launches InDi Molecular
  • Endocyte Signs Licensing Agreement with Endocyte for etarfolatide Cancer Diagnostic Imaging Agent
  • Siemens' PETNET Solutions Signs Agreement with Navidea Biopharmaceuticals
  • Eli Lilly to Acquire two Alzheimer's Imaging Agents from Siemens
  • Siemens PETNET Solutions Expands Manufacturing and Distribution of Amyvid

9. FOCUS ON SELECT PLAYERS

  • Aytu BioScience, Inc. (US)
  • Bayer Healthcare Pharmaceuticals (Germany)
  • Bracco Diagnostics, Inc. (US)
  • Daiichi Sankyo Company Limited (Japan)
  • Eisai Co., Ltd. (Japan)
  • Eli Lilly and Company (US)
  • GE Healthcare (UK)
  • Guerbet Group (France)
  • Lantheus Medical Imaging, Inc. (US)
  • Mallinckrodt plc (Ireland)

10. GLOBAL MARKET PERSPECTIVE

    • Table 21: World Recent Past, Current & Future Analysis for Imaging Agents by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East & Africa and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 22: World Historic Review for Imaging Agents by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East & Africa and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 23: World 14-Year Perspective for Imaging Agents by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East & Africa and Latin America Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)
    • Table 24: World Recent Past, Current & Future Analysis for Contrast Media by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East & Africa and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 25: World Historic Review for Contrast Media by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East & Africa and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 26: World 14-Year Perspective for Contrast Media by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East & Africa and Latin America Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)
    • Table 27: World Recent Past, Current & Future Analysis for Contrast Media by Product Segment - X-Ray/CT, MRI and Ultrasound Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 28: World Historic Review for Contrast Media by Product Segment - X-Ray/CT, MRI and Ultrasound Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 29: World 14-Year Perspective for Contrast Media by Product Segment - Percentage Breakdown of Dollar Sales for X-Ray/CT, MRI and Ultrasound Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)
    • Table 30: World Recent Past, Current & Future Analysis for X-Ray/CT Contrast Media by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East & Africa and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 31: World Historic Review for X-ray/CT Contrast Media by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East & Africa and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 32: World 14-Year Perspective for X-Ray/CT Contrast Media by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East & Africa and Latin America Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)
    • Table 33: World Recent Past, Current & Future Analysis for MRI Contrast Media by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East & Africa and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 34: World Historic Review for MRI Contrast Media by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East & Africa and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 35: World 14-Year Perspective for MRI Contrast Media by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East & Africa and Latin America Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)
    • Table 36: World Recent Past, Current & Future Analysis for Ultrasound Contrast Media by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East & Africa and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 37: World Historic Review for Ultrasound Contrast Media by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East & Africa and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 38: World 14-Year Perspective for Ultrasound Contrast Media by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East & Africa and Latin America Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)
    • Table 39: World Recent Past, Current & Future Analysis for Diagnostic Radiopharmaceuticals by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East & Africa and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 40: World Historic Review for Diagnostic Radiopharmaceuticals by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East & Africa and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 41: World 14-Year Perspective for Diagnostic Radiopharmaceuticals by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East & Africa and Latin America Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

  • A. Market Analysis
    • Contrast Media Market to Witness Slow but Steady Growth
    • Table 42: US Contrast Media Market by Leading Players (2013): Percentage Dollar Share Breakdown for Bayer, Bracco, GE Healthcare, Mallinckrodt and Others (includes corresponding Graph/Chart)
    • Diagnostic Radiopharmaceuticals to Drive Future Growth
    • Table 43: US Nuclear Imaging Market (2015): Percentage Share Breakdown of Procedure Volume for SPECT and PET (includes corresponding Graph/Chart)
    • Table 44: US Market for Diagnostic Radiopharmaceuticals Agents (2015E): Percentage Share Breakdown of Value Sales for Cardiology and Non-Cardiology Applications (includes corresponding Graph/Chart)
    • Growth Stimulants in a Nut Shell
    • Demographic Changes Offer Growth Opportunities
    • Table 45: North American Aging Population by Age Group: 1975-2050 (includes corresponding Graph/Chart)
    • Dynamics of Pricing
    • Key Trends and Issues
      • Expanding Applications to Stimulate Growth in Dx Radiopharmaceuticals Market
      • New Oncology, Neurology Agents to Boost Growth
      • Managing Alzheimer's Opens New Avenues for Imaging Agents
      • List of FDA Approved Alzheimer's Diagnostic Imaging Agents
      • Alzheimer's Stats
    • Table 46: Alzheimer's Prevalence in the US (2015): As a Percentage of Population by Age-Group (includes corresponding Graph/Chart)
    • Table 47: Alzheimer's Prevalence in the US by State: 2016 & 2025 (includes corresponding Graph/Chart)
      • Nuclear Cardiology Products Drive Diagnostic Radiopharmaceuticals Market
      • Cardiovascular Imaging to Lead Volume Growth
      • PET Procedures in the US on Rise
    • Table 48: US PET Market by Leading Players (2013): Percentage Market Share Breakdown of Value Sales for GE Healthcare, Philips Healthcare, Siemens Healthcare and Others (includes corresponding Graph/Chart)
      • Growing Adoption of SPECT/CT
      • Rising Incidence of Cancer - A Major Growth Driver
    • Table 49: New Cancer Cases by Gender and Affected Site in the US (2015) (includes corresponding Graph/Chart)
      • Isotope Shortage Leads to Dependence on Imports
      • Shortage of Medical Isotopes Looms Large
    • Table 50: Nuclear Reactors Producing 99Mo: Potential Annual Output and Estimated Year of Ceasing Production (includes corresponding Graph/Chart)
    • Table 51: National Programs for New Molybdenum 99 Capacity: Annual Production Estimates and Current Status
      • DOE's Flawed Isotope Program Adds to the Woe
      • US Fluorodeoxyglucose (FDG) Market: An Overview
    • Table 52: US FDG Market by Procedure Type (2012): Percentage Share Breakdown of Procedure Volume for Oncology, Neurology, and Cardiology (includes corresponding Graph/Chart)
    • Competitive Analysis - Imaging Market
    • Regulatory Environment
      • Provisions Regarding Off-Label Usage of Contrast Media
      • Reimbursement Issues
      • Contrast Agents and Diagnostic Radiopharmaceuticals Bundled As Supplies
    • Table 53: CT Reimbursement Changes: CPT Codes for CT and CT Angiography and Payment Rates for 2015 and 2016
    • Table 54: MRI Reimbursement Changes: CPT Codes for MRI and MR Angiography (MRA) and Payment Rates for 2015 and 2016
    • Product Launches/Approvals
    • Strategic Corporate Developments
    • Key Players
  • B. Market Analytics
    • Table 55: US Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 56: US Historic Review for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 57: US 14-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

2. CANADA

  • A. Market Analysis
    • Current and Future Analysis
    • An Overview of Medical Imaging Market
    • Table 58: Percentage Distribution of Canadian Population by Age Group: 2015 (includes corresponding Graph/Chart)
    • Canadian Scientists Discover Remedy for Isotope Shortages
    • Regulatory and Legal Restrictions
    • Strategic Corporate Developments
  • B. Market Analytics
    • Table 59: Canadian Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 60: Canadian Historic Review for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 61: Canadian 14-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

3. JAPAN

  • A. Market Analysis
    • Current and Future Analysis
      • Demographics Drive Market Growth
    • Table 62: Japanese Population by Age Group (2015) (includes corresponding Graph/Chart)
    • Table 63: Japanese 65+ Years Population: 1950-2010 (includes corresponding Graph/Chart)
    • Number of Nuclear Medicine Procedures on the Rise
    • Reimbursement Issues
    • Product Approval
    • Strategic Corporate Developments
    • Key Players
  • B. Market Analytics
    • Table 64: Japanese Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 65: Japanese Historic Review for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 66: Japanese 14-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

4. EUROPE

  • A. Market Analysis
    • Outlook
    • Nuclear Medicine Imaging Equipment Market: An Overview
    • Table 67: European Installed Base for Diagnostic Imaging Equipment by Modality (2013): Percentage Share Breakdown of Volume Installations for SPECT, PET/CT, SPECT/CT, Planar, Cardiac SPECT, and PET/MR (includes corresponding Graph/Chart)
    • Cancer: A Major Driver for Diagnostic Radiopharmaceuticals
    • Table 68: Cancer Incidence in Europe by Site: 2012 (in Thousands) (includes corresponding Graph/Chart)
    • Ageing Demography - An Opportunity Indicator
    • Table 69: Population Breakup by Age Group for EU-28 Countries: 2015 (as a Percentage of Total Population) (includes corresponding Graph/Chart)
    • Reimbursement
    • Outsourcing of Imaging Diagnostics
      • Distribution Structure
      • Direct Sales
      • License Agreements
      • Distribution Agreements
      • A Price Sensitive Market
    • Macro Environment
      • Germany
      • France
      • Spain & Italy
      • Scandinavia
    • Product Approval
  • B. Market Analytics
    • Table 70: European Recent Past, Current & Future Analysis for Imaging Agents by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 71: European Historic Review for Imaging Agents by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 72: European 14-Year Perspective for Imaging Agents by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)
    • Table 73: European Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 74: European Historic Review for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 75: European 14-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

4a. FRANCE

  • A. Market Analysis
    • Current and Future Analysis
    • Growth Stimulants
    • Strategic Corporate Developments
    • Guerbet Group - A Key Player
  • B. Market Analytics
    • Table 76: French Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 77: French Historic Review for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 78: French 14-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

4b. GERMANY

  • A. Market Analysis
    • Current and Future Analysis
    • Strategic Corporate Development
    • Bayer Healthcare Pharmaceuticals - A Key Player
  • B. Market Analytics
    • Table 79: German Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 80: German Historic Review for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 81: German 14-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

4c. ITALY

  • A. Market Analysis
    • Current and Future Analysis
    • Strategic Corporate Development
  • B. Market Analytics
    • Table 82: Italian Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 83: Italian Historic Review for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 84: Italian 14-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

4d. THE UNITED KINGDOM

  • A. Market Analysis
    • Current and Future Analysis
    • Strategic Corporate Development
    • GE Healthcare - A Major UK-Based Player
  • B. Market Analytics
    • Table 85: UK Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 86: UK Historic Review for Imaging Agents by Product Segment - Contrast Media (X-Ray/ CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 87: UK 14-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

4e. SPAIN

  • Market Analysis
    • Table 88: Spanish Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 89: Spanish Historic Review for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 90: Spanish 14-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

4f. RUSSIA

  • A. Market Analysis
    • Current and Future Analysis
    • Strategic Corporate Development
  • B. Market Analytics
    • Table 91: Russian Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 92: Russian Historic Review for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 93: Russian 14-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

4g. REST OF EUROPE

  • A. Market Analysis
    • Current and Future Analysis
    • Product Approvals
    • Strategic Corporate Developments
    • Mallinckrodt plc - A Major Irish Manufacturer of Nuclear Imaging Agents
  • B. Market Analytics
    • Table 94: Rest of Europe Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 95: Rest of Europe Historic Review for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 96: Rest of Europe 14-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC

  • A. Market Analysis
    • Current and Future Analysis
    • Healthcare Spending in Asia-Pacific: On the Rise
    • Aging Populace - Potential Opportunities
    • Table 97: Over 65 Years Individuals as % of Total Population in Select Asian Countries: 2015 (includes corresponding Graph/Chart)
    • India & China Offer Significant Growth Opportunities
    • MRI Market in Asia
  • B. Market Analytics
    • Table 98: Asia-Pacific Recent Past, Current & Future Analysis for Imaging Agents by Geographic Region - China, India and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 99: Asia-Pacific Historic Review for Imaging Agents by Geographic Region - China, India and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 100: Asia-Pacific 14-Year Perspective for Imaging Agents by Geographic Region - Percentage Breakdown of Dollar Sales for China, India and Rest of Asia-Pacific Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)
    • Table 101: Asia-Pacific Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 102: Asia-Pacific Historic Review for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 103: Asia-Pacific 14-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

5a. CHINA

  • A. Market Analysis
    • Current and Future Analysis
    • Medical Imaging Equipment Market - An Overview
    • Increasing Expenditure on Healthcare Sector
    • Competitive Scenario
    • Table 104: Leading Players in the Chinese CT Contrast Agents Market (2015): Percentage Breakdown of Value Sales for Select Agents (includes corresponding Graph/Chart)
    • Table 105: Leading Players in the Chinese MRI Contrast Agents Market (2015): Percentage Breakdown of Value Sales for Select Agents (includes corresponding Graph/Chart)
    • Strategic Corporate Developments
  • B. Market Analytics
    • Table 106: Chinese Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 107: Chinese Historic Review for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 108: Chinese 14-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

5b. INDIA

  • A. Market Analysis
    • India - A High Potential Market
    • Regulatory Mechanism for Guiding Isotope Production and Distribution
    • Overview of CT Scanners Market in India
    • PET/CT Scanning in India Gathers Momentum
    • J.B.Chemicals and Pharmaceuticals Ltd - A Key Player
  • B. Market Analytics
    • Table 109: Indian Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 110: Indian Historic Review for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 111: Indian 14-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

5c. REST OF ASIA-PACIFIC

  • A. Market Analysis
    • Current and Future Analysis
    • Korea
    • Strategic Corporate Development
  • B. Market Analytics
    • Table 112: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-Ray/ CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 113: Rest of Asia-Pacific Historic Review for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 114: Rest of Asia-Pacific 14-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

6. THE MIDDLE EAST & AFRICA

  • Market Analysis
    • Table 115: Middle East & African Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-Ray/ CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 116: Middle East & African Historic Review for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 117: Middle East & African 14-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

7. LATIN AMERICA

  • A. Market Analysis
    • Current and Future Analysis
    • Private Sector Boosts Healthcare Segment
  • B. Market Analytics
    • Table 118: Latin American Recent Past, Current & Future Analysis for Imaging Agents by Geographic Region - Brazil and Rest of Latin American Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 119: Latin American Historic Review for Imaging Agents by Geographic Region - Brazil and Rest of Latin American Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 120: Latin American 14-Year Perspective for Imaging Agents by Geographic Region - Percentage Breakdown of Dollar Sales for Brazil and Rest of Latin American Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)
    • Table 121: Latin American Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 122: Latin American Historic Review for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 123: Latin American 14-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

7a. BRAZIL

  • Market Analysis
    • Table 124: Brazilian Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 125: Brazilian Historic Review for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 126: Brazilian 14-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

7b. REST OF LATIN AMERICA

  • Market Analysis
    • Table 127: Rest of Latin America Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 128: Rest of Latin America Historic Review for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 129: Rest of Latin America 14-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

COMPETITIVE LANDSCAPE

Back to Top